癌—睾丸抗原SSX基因在儿童急性白血病的表达及其意义的初步研究
发布时间：2018-11-01 12:00
【摘要】：目的：本研究通过检测滑膜肉瘤X断裂点基因(synovial sarcoma X breakpoint,SSX)家族中SSX1-5基因在儿童急性白血病(acute leukemia,AL)患者外周血单个核细胞中的表达情况及其与临床特征之间的关系,初步探讨其作为AL辅助诊断和监测预后以及免疫治疗可能性。 方法：87例儿童急性白血病患者作为实验组,其中45例初诊患者为初诊组；42例经治疗达完全缓解为完全缓解组；30例非恶性疾病及血液系统疾病儿童作为对照组。采用逆转录-聚合酶链反应(reverse transcriptase polymerase chain reaction, RT-PCR)技术,对各组中儿童外周血单个核细胞进行SSX1-5mRNA表达的检测。同时结合患者的临床资料,对SSX1-5mRNA的表达与临床特征(性别、年龄、诊断时外周血白细胞计数、FAB分型、临床危险度分型、免疫学分型)、完全缓解率、复发的关系进行分析。 结果：(1)DNA测序证实PCR阳性产物为目的基因。(2) SSX1-5基因的表达：45例初诊组患者外周血中,SSX1-4基因的表达率分别为：60.0%(27/45)、17.8%(8/45)、31.1%(14/45)、8.9%(4/45),未检测到SSX5基因的表达；至少表达1个SSX基因者达80.0%(36/45)；表达2个或2个以上者达28.9%(13/45)；表达3个达2.2%(1/45)。42例完全缓解组SSX1-5基因的表达率分别为：66.7%(28/42)、16.7%(7/42)、26.2%(11/42)、4.8%(2/42)、2.4%(1/42)；至少表达1个SSX基因者达85.7%(36/42)；表达2个或2个以上者达26.2%(11/42)；表达3个达4.8%(2/42)。30例对照组SSX1、3的表达率分别为16.7%(5/30)、6.7%(2/30),未检测到SSX2、4、5基因的表达。以上的检测结果经统计学分析(SPSS13.0统计学分析软件),其结果如下：①SSX1和SSX3基因在初诊组与完全缓解组的表达率均明显高于对照组(P0.05)；②SSX1-5基因在初诊组和完全缓解组的表达率无明显差异(P0.05。(3)SSX1-5基因在初诊组ALL表达率与临床特征的关系：SSX1mRNA在高危年龄组(≥10岁)表达率为100%(9/9)显著高于在低危年龄组(1～10岁)的表达率为44%(11/25)。SSX2mRNA在外周血WBC计数≥50×109/L的患者表达率为66.7%(4/6)显著高于在外周血WBC计数50×109/L的患者表达率14.3%(4/28)。SSX3mRNA在T-ALL的表达率为80%(4/5)显著高于在B-ALL的表达率为20.7%(6/29)。(4)对初诊组和完全缓解组随访发现：①SSX1-5基因在初诊组的表达与完全缓解(completely remission, CR)率无关,初诊组的完全缓解率为97.8%；②SSX3基因在完全缓解组的表达与复发有关(P0.05) 结论：(1)SSX1-5基因在儿童AL中表达频率不同,但SSX1和SSX3基因表达率较高,有可能成为儿童AL免疫治疗的靶抗原。(2)对SSX1、2、3基因检测对评估儿童ALL患者临床治疗效果、判断预后有一定的临床意义,特别是对SSX3基因检测对于判断AL预后有较强的指导意义。
[Abstract]:Objective: to investigate the role of SSX1-5 gene in (acute leukemia, of childhood acute leukemia by detecting the SSX1-5 gene in synovial sarcoma X breakpoint gene (synovial sarcoma X breakpoint,SSX) family. The expression of peripheral blood mononuclear cells (PBMC) in patients with AL and its relationship with clinical features were preliminarily discussed as an auxiliary diagnosis and monitoring of prognosis of AL and the possibility of immunotherapy. Methods: 87 children with acute leukemia were used as experimental group, among them 45 patients were first diagnosed group, 42 patients were treated to complete remission group, and 30 children with non-malignant diseases and hematological diseases were used as control group. Reverse transcription-polymerase chain reaction (reverse transcriptase polymerase chain reaction, RT-PCR) technique was used to detect the expression of SSX1-5mRNA in peripheral blood mononuclear cells (PBMC) of children in each group. At the same time, the expression and clinical characteristics of SSX1-5mRNA (sex, age, peripheral blood leukocyte count, FAB classification, clinical risk classification, immunological classification), complete remission rate, were analyzed in combination with the clinical data of the patients. The relationship between recurrence and recurrence was analyzed. Results: (1) DNA sequencing confirmed that the PCR positive product was the target gene. (2) the expression of SSX1-5 gene: the expression rate of SSX1-4 gene was 60.0% (27 / 45) in the peripheral blood of 45 newly diagnosed patients. SSX5 gene expression was not detected in 17. 8% (8 / 45), 31. 1% (14 / 45), 8. 9% (4 / 45); The expression of at least one SSX gene was 80.0% (36 / 45), and the expression of two or more SSX genes was 28.9% (13 / 45). The expression rates of SSX1-5 gene in 42 complete remission groups were 66.7% (28 / 42), 16.7% (7 / 42), 26.2% (11 / 42), 4.8% (2 / 42), respectively. 2.4% (1 / 42); The expression of at least one SSX gene was 85.7% (36 / 42), and the expression of two or more SSX genes was 26.2% (11 / 42). The expression rates of SSX1,3 were 16.7% (5 / 30) and 6.7% (2 / 30) in 30 controls, respectively. No SSX2,4,5 gene expression was detected. The results were as follows: the expression rate of 1SSX1 and SSX3 gene in the first diagnosis group and complete remission group were significantly higher than that in the control group (P0.05). There was no significant difference between the expression rate of 2SSX1-5 gene in the first visit group and the complete remission group (P0.05. (3) the relationship between the ALL expression rate of the SSX1-5 gene in the first visit group and the clinical characteristics: the expression rate of SSX1mRNA in the high-risk age group (鈮，
本文编号：2303871
[Abstract]:Objective: to investigate the role of SSX1-5 gene in (acute leukemia, of childhood acute leukemia by detecting the SSX1-5 gene in synovial sarcoma X breakpoint gene (synovial sarcoma X breakpoint,SSX) family. The expression of peripheral blood mononuclear cells (PBMC) in patients with AL and its relationship with clinical features were preliminarily discussed as an auxiliary diagnosis and monitoring of prognosis of AL and the possibility of immunotherapy. Methods: 87 children with acute leukemia were used as experimental group, among them 45 patients were first diagnosed group, 42 patients were treated to complete remission group, and 30 children with non-malignant diseases and hematological diseases were used as control group. Reverse transcription-polymerase chain reaction (reverse transcriptase polymerase chain reaction, RT-PCR) technique was used to detect the expression of SSX1-5mRNA in peripheral blood mononuclear cells (PBMC) of children in each group. At the same time, the expression and clinical characteristics of SSX1-5mRNA (sex, age, peripheral blood leukocyte count, FAB classification, clinical risk classification, immunological classification), complete remission rate, were analyzed in combination with the clinical data of the patients. The relationship between recurrence and recurrence was analyzed. Results: (1) DNA sequencing confirmed that the PCR positive product was the target gene. (2) the expression of SSX1-5 gene: the expression rate of SSX1-4 gene was 60.0% (27 / 45) in the peripheral blood of 45 newly diagnosed patients. SSX5 gene expression was not detected in 17. 8% (8 / 45), 31. 1% (14 / 45), 8. 9% (4 / 45); The expression of at least one SSX gene was 80.0% (36 / 45), and the expression of two or more SSX genes was 28.9% (13 / 45). The expression rates of SSX1-5 gene in 42 complete remission groups were 66.7% (28 / 42), 16.7% (7 / 42), 26.2% (11 / 42), 4.8% (2 / 42), respectively. 2.4% (1 / 42); The expression of at least one SSX gene was 85.7% (36 / 42), and the expression of two or more SSX genes was 26.2% (11 / 42). The expression rates of SSX1,3 were 16.7% (5 / 30) and 6.7% (2 / 30) in 30 controls, respectively. No SSX2,4,5 gene expression was detected. The results were as follows: the expression rate of 1SSX1 and SSX3 gene in the first diagnosis group and complete remission group were significantly higher than that in the control group (P0.05). There was no significant difference between the expression rate of 2SSX1-5 gene in the first visit group and the complete remission group (P0.05. (3) the relationship between the ALL expression rate of the SSX1-5 gene in the first visit group and the clinical characteristics: the expression rate of SSX1mRNA in the high-risk age group (鈮，
本文编号：2303871
本文链接：https://www.wllwen.com/yixuelunwen/eklw/2303871.html
最近更新
教材专著
